(RAPP) Rapport Therapeutics, Inc. Business Model Canvas Research

Rapport Therapeutics, Inc. depends on the FDA and IRBs to move IND-enabling work and clinical protocols forward, since they govern safety, trial design, and patient protection. Regulatory alignment has to stay tight at every step, because even small protocol changes can slow enrollment or delay a study start.

• FDA clears development path
• IRBs protect patient rights
• Alignment reduces trial delays

Rapport Therapeutics, Inc. relies on capital and BD partners because clinical biopharma needs outside funding to run trials and keep pipeline options open. Its June 2024 IPO raised about $177 million, and those relationships also support future licensing, expansion, and lower single-asset risk.

• Funds trials and cash runway
• Supports licensing and expansion
• Reduces single-asset dependence

Rapport Therapeutics, Inc. centers clinical development execution on its lead program, RAP-219, moving from trial design to site oversight, biomarker plan, and patient data analysis. In 2025, this work remained the main value-creation step for a 0-revenue biopharma model, where one successful study can reprice the whole company.

• Runs and sponsors patient trials
• Designs protocols and endpoints
• Manages sites and biomarker readouts
• Turns clinical data into proof

Rapport Therapeutics, Inc. uses IP and portfolio management to protect its chemistry platform and its pipeline across TARPγ8 and nAChR biology, keeping room for follow-on assets and partner talks. Strong patent coverage is a key defense for exclusivity, and Rapport Therapeutics, Inc. had 2 clinical-stage programs in its 2025 public pipeline disclosure.

• Defend platform chemistry
• Plan TARPγ8 and nAChR assets
• Preserve exclusivity and flexibility

Rapport Therapeutics, Inc.'s CNS biology platform is the core discovery engine behind its precision neuroscience work: it links target biology, medicinal chemistry, and translational pharmacology to find drug candidates with higher selectivity and better human relevance. This platform is meant to keep generating new assets beyond the current pipeline.

• Precision CNS target discovery
• Medicinal chemistry + translational pharmacology
• Pipeline renewal source

Rapport Therapeutics is based in Boston, Massachusetts, inside the Boston-Cambridge biotech cluster, which has more than 1,000 biotech companies and research institutions. Its scientific team and patent portfolio are core intangible assets, helping it recruit talent, form partnerships, and execute drug discovery fast.

• Boston talent pool
• Scientific know-how
• Patent protection
• Partnering edge

Rapport Therapeutics, Inc. uses small molecules, which can be made with standard chemistry, scaled with lower COGS than biologics, and moved through oral or other broad-dispersion routes; in 2025, about 90% of FDA-approved drugs were still small molecules. This format also lets Rapport tune potency, selectivity, and PK fast through iterative medicinal chemistry.

• Lower manufacturing complexity

• Broader distribution potential

• Faster chemistry optimization

RAP-199 plus the nAChR programs give Rapport Therapeutics, Inc. 2 distinct shots on goal, so the company is not tied to one clinical readout. That spread can lift the odds of long-term value creation and gives Rapport Therapeutics, Inc. more leverage in future partnering talks if one asset advances faster.

• 2 program tracks reduce single-hypothesis risk
• Diversification supports higher success odds
• More assets can improve partner leverage

Licensing partner management is critical for Rapport Therapeutics, Inc. if assets are partnered, because it must keep science and commercial teams aligned on milestones, data sharing, and co-development terms. Trust drives future deal flow; in biotech, 2025 partnering activity stayed selective, so reliable execution can matter as much as the asset itself.

• Track milestones and decision rights
• Share data fast and cleanly
• Keep co-development terms clear
• Protect trust for future deals

As a public biotech, Rapport Therapeutics, Inc. must keep investors updated on pipeline milestones, clinical risk, and cash use through SEC filings and earnings materials. That cadence protects credibility and supports future financing; in 2024, the company completed its IPO and began trading on Nasdaq, making market trust a core asset.

• SEC filings signal progress and risk.
• Investor updates support credibility.
• Trust helps future fundraising.

Rapport Therapeutics, Inc. uses SEC filings, shareholder letters, and investor decks to show pipeline progress, cash use, and trial timing to capital markets. For a clinical-stage public company, this channel directly supports financing capacity by shaping how investors read risk, runway, and data milestones.

• Quarterly and annual SEC filings
• Shareholder letters and presentations
• Updates cash runway and trial progress

Direct outreach to pharma and biotech partners helps Rapport Therapeutics, Inc. turn preclinical and early clinical assets into licensing talks, upfront cash, and milestone-based, non-dilutive funding. That matters for later-stage portfolio expansion, where deal flow can fund new programs without added equity dilution.

• Targets licensing and co-development
• Drives upfront and milestone cash
• Supports expansion without dilution

Hearing impairment patients are a focused Customer Segment for Rapport Therapeutics, Inc.'s a9a10 nAChR program, because hearing loss affects about 1.5 billion people worldwide and 430 million need rehab. Otology and audiology clinicians matter most here, since the impact is daily, high, and tied to speech, work, and social function.

• Large global need: 1.5 billion
• Disabling cases: 430 million
• Key users: otology, audiology
• Value driver: quality of life

Rapport Therapeutics, Inc. is pre-commercial, so its main economic buyers are pharma partners that can license, co-fund, or buy assets before launch; that can fund R&D without waiting for product sales. Payers matter later, if any program reaches market, because they will shape pricing, formulary access, and reimbursement.

• Pharma partners fund development
• Deals can include licensing or acquisition
• Payers matter after approval

Regulatory and IP legal costs are fixed overhead for Rapport Therapeutics, Inc., covering IND work, patent filing, prosecution, and outside counsel. In U.S. biotech, an IND starts a 30-day FDA review clock, and patent protection can last 20 years from filing, so this spend protects the platform and scales across programs.

• IND prep and FDA strategy recur each program
• Patent filings protect multi-program platform value
• Counsel and prosecution add steady fixed overhead

Rapport Therapeutics, Inc. keeps G&A and public-company costs high because its Boston HQ must fund finance, audit, reporting, and compliance work, plus the internal controls needed for SEC reporting. That overhead supports the operating model, but it also adds steady burn that does not directly drive drug development.

• Boston HQ adds fixed overhead
• Finance and audit raise burn
• SEC disclosure needs controls
• G&A supports the core model

Development and milestone payments are a key biotech revenue stream for Rapport Therapeutics, Inc.: partners pay when a program clears preclinical, clinical, or regulatory gates, so cash arrives as technical risk drops. In recent biotech deals, total milestone pools often run into the tens or hundreds of millions of dollars, which can cut near-term financing pressure without giving up all future upside.

• Paid on technical progress
• Can fund trials faster
• Often worth tens of millions

Rapport Therapeutics, Inc. can only get future royalties or product sales if one of its assets clears clinical trials and wins regulatory approval. In partnered drug deals, royalties often run in the single-digit to low-teens percentage range, but for Rapport this stream is still zero until a program reaches market.

• Depends on clinical success
• Needs regulatory approval first
• Could become sales or royalties